Biotech Values

[DewDiligence]

If MRK’s Voaxpaxar is approved, it will be one of the more unlikely drug turnarounds in recent history.

Has anyone seen recent analysts’ forecasts for Vorapaxar? They must be way down from what they were before the clinical setbacks that relegated Vorapaxar to a niche product rather a general-purpose replacement for Plavix.

p.s. Tomorrow’s FDA advisory panel on Voapaxar is being webcast live, but there’s strong competition from the webcasts at JPM.